Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology firm Stoke Therapeutics raises $90m financing
Stoke Therapeutics, a US-based biotechnology company focused on the development of drugs for severe genetic diseases, has raised $90m in a Series B financing round.
Research & Development
-
24 Oct 2018
-
24 Oct 2018
Bain Capital, Pfizer create new CNS company Cerevel Therapeutics
Private equity firm Bain Capital has joined forces with US pharma giant Pfizer to create a new biopharmaceutical company, dubbed Cerevel Therapeutics, which will focus on developing drugs for the treatment of central nervous system (CNS) disorders.
-
24 Oct 2018
CANbridge, WuXi Biologics collaborate on rare disease therapeutics
China-based biopharmaceutical firm CANbridge Pharmaceutical and global open-access biologics technology platform company WuXi Biologics have entered into a partnership for rare disease therapeutics.
-
23 Oct 2018
FSD Pharma signs binding LOI to buy Therapix Biosciences
FSD Pharma has signed a binding letter of intent (LOI) to acquire Therapix Biosciences, a NASDAQ traded pharmaceutical company focused on the development of Cannabinoid-based treatments.
-
22 Oct 2018
Oncology startup TP Therapeutics raises $80m in financing
TP Therapeutics, a San Diego-based clinical-stage precision oncology company, has raised $80m in a new funding round led by Foresite Capital and venBio Partners.
-
19 Oct 2018
AbbVie, Morphic Therapeutic to advance therapeutic for fibrotic diseases
AbbVie and Morphic Therapeutic have entered into a research and development collaboration, designed to advance multiple Morphic's oral integrin therapeutics for fibrosis-related indications.
-
19 Oct 2018
Novartis to acquire biopharmaceutical firm Endocyte for $2.1bn
Swiss drugmaker Novartis has agreed to acquire US-based biopharmaceutical firm, Endocyte, in a deal valued at around $2.1bn.
-
18 Oct 2018
Diurnal puts hold on US development of adrenal drug Chronocort
Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
-
17 Oct 2018
US firm Revolution Medicines buys Warp Drive Bio
US-based Revolution Medicines has acquired Warp Drive Bio for an undisclosed sum as part of its efforts to expand drug discovery portfolio.
-
16 Oct 2018
HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics
HiFiBiO Therapeutics has acquired H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.